Skip To Main Content
Peter Maybarduk on Muck Rack

Peter Maybarduk

East Coast United States, Washington
As seen in: POLITICO Europe, Geneva Health Files, Public Citizen, InfoJustice
Access to Medicines Director @Public_Citizen, Board @MedsPatentPool, public interest IP lawyer, songwriter under Creative Commons. See: www.citizen.org/access
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Peter

Contact Peter, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Big Pharma is using tariffs to hold Europe to ransom

|
By Nick Dearden, Peter Maybarduk
| POLITICO Europe Verified
Nick Dearden is the director of Global Justice Now. Peter Maybarduk is the Access to Medicines director of Public Citizen. Both are members of the People’s Medicines Alliance. U.S. President Donald Trump has more tariff chaos up his sleeve, and medicine in his sights. This week, he issued an executive order blaming America’s sky-high drug prices on other countries — and pharmaceutical tariffs could be next. Advertisement Panic is starting to set in.
Open in Who Shared View Duplicates (2) Issue with article?

[EXCLUSIVE] Lobbying Disclosures in the US: How Big Pharma Fought the TRIPS Waiver & is Pushing for Strong Intellectual Property Protection in the Pandemic Agreement

|
By Peter Maybarduk, Michael Weinstein Verified, Priti Patnaik Verified
| Geneva Health Files
Hi, If you have trouble understanding why international diplomacy is a vastly unequal field, or in mapping the scale of corporate power in determining public health outcomes, read our edition today.
Open in Who Shared Issue with article?

Mpox Vaccine Access

|
By Peter Maybarduk, Megan Whiteman
| Public Citizen
Public Citizen Menu The world is reckoning with the second World Health Organization emergency declaration for mpox in as many years. A key tool to combat the virus, the MVA-BN mpox vaccine, owes its existence to two decades and billions of dollars worth of U.S. government investment. Despite profound public support, the vaccine’s manufacturer, Bavarian Nordic, remains the sole supplier of MVA-BN and has done far too little to enable access to its vaccine outside of wealthy countries.
Open in Who Shared Issue with article?
See all 9 articles